• BIOMUNEX has a strong IP position.
  • BiXAb® bispecific antibody platform has been developed based on an original bispecific format licensed to BIOMUNEX by a pan-European academic Consortium.
  • BIOMUNEX is actively developing new intellectual property based on its own R&D efforts and in collaboration with academic teams and industrial partners.
  • Various patent applications were filed by BIOMUNEX in 2016 and 2017:
    • BIOMUNEX has filed several patent applications on the BiXAb® Platform.
    • BIOMUNEX has also filed several patent applications for its BiXAb® lead products.